抗CD4单抗-表阿霉素在体外和体内对T源性淋巴瘤的作用

The effect of anti-CD4-epirubicin to T lymphoma in vitro and in vivo

目的:探讨抗CD4单克隆抗体免疫结合物对T源性淋巴瘤细胞的特异性杀伤效应。方法:采用低分子右旋糖苷(DextranT10)作联接桥,将表阿霉素分子偶联到抗CD4单抗上,制备成抗CD4单抗免疫结合物,在体外和体内,经补体非依赖性细胞毒试验、免疫组化试验、CFU-GM集落形成试验、125I-单抗结合物裸鼠体内示踪等方法测定抗CD4免疫结合物对T-源性淋巴瘤细胞的亲合力和特异性杀伤效应。结果:抗CD4-表阿霉素免疫结合物对T源性淋巴瘤细胞(CEM)有较强亲合力和特异性杀伤力(79%),ECT扫描发现125I-抗CD4结合物主要富集在含CEM细胞的实体瘤内。结论:125I-抗CD4单抗标志物和抗CD4-表阿霉素结合物可用于诊断和治疗T-源性淋巴瘤。

Objective：To detect the specificity killing effect of anti-CIM-epirubicin immunoconjugate on T origin lymphoma cells. Methods：The immunoconjugate was made by linking anti-CIM monoclonal antibody with epirubicin using Dextran T10 as linkage. The affinity and the killing effect of the immunoconjagate in vitro and in vlvo were detected by complement independent cytotoxicity, immuno-histochemistry, CFU-GM and ^125I-anti-CIM radio-immuno-imaging in nude mice. Results： Anti-CIM immunoconjugate showed a strong attlnity and specific killing effect to T origin lymphoma CEM cells. Concluslon：Anti-CIM-epirubicin and ^125I-anti-CIM could be used for diagnosis and treatment of T origin lymphoma.